Benchmark Downgrades RTI Biologics (RTIX) to Hold; Shares Reflect Recent Progress
Get Alerts RTIX Hot Sheet
Price: $3.14 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Benchmark downgraded RTI Biologics (NASDAQ: RTIX) to Hold. PT $3.
Benchmark analyst says, "There appear to be early signs of improving end-market demand in the Sports Medicine and Dental businesses but we feel there are better opportunities to leverage a potential economic recovery. We continue to support management’s plan to diversify the business away from the troubled Spine segment; however, lacking greater visibility, we feel shares are fairly valued."
For more ratings news on RTI Biologics click here and for the rating history of RTI Biologics click here.
Shares of RTI Biologics closed at $3.02 yesterday.
Benchmark analyst says, "There appear to be early signs of improving end-market demand in the Sports Medicine and Dental businesses but we feel there are better opportunities to leverage a potential economic recovery. We continue to support management’s plan to diversify the business away from the troubled Spine segment; however, lacking greater visibility, we feel shares are fairly valued."
For more ratings news on RTI Biologics click here and for the rating history of RTI Biologics click here.
Shares of RTI Biologics closed at $3.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Kepler Cheuvreux Downgrades Avantium N.V (AVTX:NA) to Reduce
- UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share